Health Canada Santé Canada

STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Stiripentol

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled ☐
Not Controlled ✓

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substance is not structurally similar to any of the substances included in the schedules to the CDSA.

Prepared by: _____ Date: Jan 11th, 2012
Evelyn C Soo

Verified by: _____ Date: _____
Mark Kozlowski

Approved by: _____ Date: _____
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: Michelle Brittain, Inspectorate

Drug Status Report

Drug: Stiripentol

Drug Name Status: Stiripentol is the proper (INN) name.

Chemical Name: 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol

Other Names: 4,4-Dimethyl-1((3,4-methylenedioxy)phenyl-1-penten-3-ol; Diacomit

Chemical structure:



Molecular Formula: $C_{14}H_{18}O_3$

Pharmacological class / Application: Anticonvulsant

CAS-RN: 49763-96-4

International status:

US: Stiripentol is not listed in the *US Controlled Substances Act* and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances Under International Control.

Canadian Status: Stiripentol is not listed in the CDSA. The substance is used for the control of seizures, particularly Dravet syndrome,[1] and is not structurally similar to any substances listed in thes schedules to the CDSA.

Recommendation: Stiripentol is not included in the schedules to the CDSA and is not a controlled substance.

Date: January 11, 2012

---

[1]Fisher, JL. (2011) The effects of stiripentol on GABAA receptors, Epilepsia, 52 (Suppl 2):76-78.